Recombinant Anti-CEA x Anti-TNFα Bispecific Antibody (scFv-CH1/CL) is designed to be expressed as two chains. One scFv from an anti-CEA antibody variable domain is fused to CH1 and the other scFv from an anti-TNFα antibody variable domain fused to CL, or vice versa. And the CH1 and CL domains are linked covalently via a natural disulfide bond. This BsAb can retarget cytokine (TNFα) to tumor cells. It is designed for the research of Breast cancer; Ovary cancer; Colon cancer; Lung cancer therapy.